These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence. Saratzis A; Kitas GD; Saratzis N; Melas N Angiology; 2010 Feb; 61(2):137-44. PubMed ID: 19625274 [TBL] [Abstract][Full Text] [Related]
9. Does reversal of oxidative stress and inflammation provide vascular protection? Koh KK; Oh PC; Quon MJ Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298 [TBL] [Abstract][Full Text] [Related]
10. Role of the renin-angiotensin system on abdominal aortic aneurysms. Malekzadeh S; Fraga-Silva RA; Trachet B; Montecucco F; Mach F; Stergiopulos N Eur J Clin Invest; 2013 Dec; 43(12):1328-38. PubMed ID: 24138426 [TBL] [Abstract][Full Text] [Related]
11. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Evans J; Powell JT; Schwalbe E; Loftus IM; Thompson MM Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):302-3. PubMed ID: 17574455 [TBL] [Abstract][Full Text] [Related]
12. [Optimizing medical treatment of abdominal aortic aneurysm: Interest of vascular centers]. Madika AL; Mounier-Vehier C; Azzaoui R Presse Med; 2018 Feb; 47(2):161-166. PubMed ID: 29499996 [TBL] [Abstract][Full Text] [Related]
13. The influence of total plasma homocysteine and traditional atherosclerotic risk factors on degree of abdominal aortic aneurysm tissue inflammation. Arapoglou V; Kondi-Pafiti A; Rizos D; Kotsis T; Kalkandis C; Katsenis K Vasc Endovascular Surg; 2009; 43(5):473-9. PubMed ID: 19640909 [TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Wilson WR; Evans J; Bell PR; Thompson MM Eur J Vasc Endovasc Surg; 2005 Sep; 30(3):259-62. PubMed ID: 16009575 [TBL] [Abstract][Full Text] [Related]
15. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. VAN KUIJK JP; FLU WJ; WITTEVEEN OP; VOUTE M; BAX JJ; POLDERMANS D J Cardiovasc Surg (Torino); 2009 Oct; 50(5):599-609. PubMed ID: 19741575 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update. Wang YD; Liu ZJ; Ren J; Xiang MX Curr Vasc Pharmacol; 2018 Jan; 16(2):114-124. PubMed ID: 28412911 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological therapy for patients with abdominal aortic aneurysm. Assar AN Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):999-1009. PubMed ID: 19673677 [TBL] [Abstract][Full Text] [Related]
18. Medical management of small abdominal aortic aneurysms. Baxter BT; Terrin MC; Dalman RL Circulation; 2008 Apr; 117(14):1883-9. PubMed ID: 18391122 [TBL] [Abstract][Full Text] [Related]
20. Do cathepsins play a role in abdominal aortic aneurysm pathogenesis? Sukhova GK; Shi GP Ann N Y Acad Sci; 2006 Nov; 1085():161-9. PubMed ID: 17182932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]